Recent Updates
Recently added Catalysts
ANIP Positive Sentiment Score: 70/100

ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET

Key Takeaway: ANI Pharmaceuticals will release its first quarter 2026 financial results on May 8, 2026. The announcement includes a conference call and webcast hosted by key executives to discuss the results. The company emphasizes its commitment to developing innovative therapeutics and sustainable growth in its Rare Disease business.

Market Sentiment Analysis

POSITIVE FACTORS

  • ANI Pharmaceuticals is committed to improving patient lives.
  • The company is focused on sustainable growth through its Rare Disease business.
  • The upcoming financial results may indicate positive performance.

Full Press Release Details

PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its first quarter 2026 financial results on Friday, May 8, 2026, prior to the market open.
Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results.
To view the webcast, please clickhere. Links to access the webcast and conference call will also be available on the “Events & Presentations” page of the Company’s website athttps://www.anipharmaceuticals.com, under the “Investors” section. A replay of the event will remain accessible for up to one year.
About ANIANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visithttps://www.anipharmaceuticals.com.

Investor Relations:Courtney Mogerley, Argot PartnersT: 646-368-8014E:ani@argotpartners.com

Media Relations:Argot PartnersT: 212-600-1494E:ani@argotpartners.com

Frequently Asked Questions

When will ANI Pharmaceuticals release its Q1 2026 results?

ANI Pharmaceuticals will release its Q1 2026 financial results on May 8, 2026.

Who will host the conference call for the results?

The conference call will be hosted by Nikhil Lalwani and other key executives.

How can investors access the webcast?

Investors can access the webcast via the 'Events & Presentations' page on the company's website.

What is ANI Pharmaceuticals' focus area?

ANI Pharmaceuticals focuses on developing innovative therapeutics in various medical fields.

Last updated: Apr 24, 2026